来自官方财务报表的收入、利润与现金流历史。
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| 总收入 | ₹54.1B | ₹45.9B | ₹41.6B | ₹37.1B | — |
| 毛利 | ₹41.6B | ₹34.6B | ₹30.5B | ₹25.9B | — |
| 营业利润（EBIT） | ₹13.3B | ₹11.3B | ₹10.5B | ₹6.8B | — |
| 净利 | ₹10.6B | ₹9.2B | ₹8.2B | ₹5.9B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 AJANTPHARM 交互式查看器。 /companies/us/AJANTPHARM
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms